This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: M.D.C., Amedisys, KBR, Holly Energy and SkyWest
by Zacks Equity Research
The Zacks Analyst Blog Highlights: M.D.C., Amedisys, KBR, Holly Energy and SkyWest
Healthcare Stock Q2 Earnings Due on Jul 31: HUM, AMED & More
by Zacks Equity Research
Healthcare stocks like HUM, AMED, CRL, TDOC and PRAH are likely to benefit from higher membership and revenues in the second quarter.
Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?
by Zacks Equity Research
Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.
5 Must-Buy Mid-Cap Stocks Ahead of Q2 Earnings This Week
by Nalak Das
Mid-cap stocks have rallied in 2019. These stocks can become very useful in a volatile trading scenario.
Is a Beat in Store for Molina Healthcare (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter earnings are likely to be cushioned by its strategic divestitures as well as cost-reduction plans, partly offset by lower revenues.
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
by Zacks Equity Research
Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas
Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Breast Health Growth Aid Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver strong third-quarter fiscal 2019 results on robust performance of the breast health segment.
Use Rising P/E Strategy to Buy 5 Winning Stocks
by Sanghamitra Saha
Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.
Can Home Health Growth Support Amedisys' (AMED) Q2 Earnings?
by Zacks Equity Research
Within Home Health, Amedisys (AMED) is expected to boost same-store volumes in Q2 via higher admissions and re-certifications.
Can Sequencing Products Drive Illumina's (ILMN) Q2 Earnings?
by Zacks Equity Research
Illumina (ILMN) is expected to deliver a strong second quarter on impressive performance by sequencing portfolio.
What's in the Offing for PerkinElmer's (PKI) Earnings in Q2?
by Zacks Equity Research
Top-line growth and robust performance at Diagnostics segment are likely to aid PerkinElmer's (PKI) Q2 earnings. However, forex is likely to be a dampener.
What's in Store for Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
We are upbeat about solid contributions from Boston Scientific's (BSX) Cardiovascular business group, which comprises Interventional Cardiology and Peripheral Interventions.
Can NovoCure's (NVCR) Steady Optune Business Aid Q2 Earnings?
by Zacks Equity Research
NovoCure (NVCR) expects to deliver a strong second quarter on solid performance by Optune business.
Will Core MedSurg Segment Drive Stryker's (SYK) Q2 Earnings?
by Zacks Equity Research
Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine and an upbeat second quarter 2019 view are likely to fuel Stryker's (SYK) Q2 earnings. However, forex might be a woe.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter (BAX) expects second-quarter revenues to decline 2% on a reported basis.
Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR
by Zacks Equity Research
Zacks.com featured highlights include: Ross Stores, Shoe Carnival, Stitch Fix, Amedisys and NVR
Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Top-Ranked Stocks Empowered by DuPont Analysis
by Sanghamitra Saha
Have more faith in DuPont analysis than simple ROE calculation and bet on these five stocks.
Amedisys Rides on New Buyouts, Strength in Personal Care Arm
by Zacks Equity Research
Amedisys' (AMED) recently-integrated Personal Care segment is attaining stability and living up to expectation.
Bet on These 5 Stocks With Exciting Interest Coverage Ratio
by Sumit Singh
Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.
Amedisys (AMED) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Amedisys (AMED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
by Zacks Equity Research
Zacks.com featured highlights include: Medifast, Shoe Carnival, Marine Products, Amedisys and NVR
Top Ranked Momentum Stocks to Buy for June 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 21st.
Bet Big on DuPont Analysis With These Top 5 Picks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than a simple ROE calculation? Bet on these five stocks then.